SCHEMBL11222723

SCHEMBL11222723

CC(=O)Nc1cccc(-c2cccnc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.64
ALDH1A1 P00352 2/20 0.61
HPGD P15428 1/20 0.61
HSD17B10 Q99714 1/20 0.61
CYP11B1 P15538 2/20 0.60
CYP11B2 P19099 2/20 0.60
CYP17A1 P05093 2/20 0.60
ATR Q13535 1/20 0.59
PIP4K2A P48426 1/20 0.59
PIP4K2B P78356 1/20 0.59
KMT2A Q03164 3/20 0.57
LMNA P02545 1/20 0.57
POLB P06746 1/20 0.57
PKM P14618 1/20 0.57
FYN P06241 2/20 0.57
PIK3CA P42336 1/20 0.55
PIK3CG P48736 1/20 0.55
BRAF P15056 2/20 0.55
HTT P42858 1/20 0.55
KMO O15229 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2646435 0.86 CNR1 (0.63) CNR1ALDH1A1HSD17B10CYP11B1CYP11B2
SCHEMBL27811101 0.86 CNR1 (0.66) CNR1ALDH1A1LMNAPKMHTT
SCHEMBL196216 0.84 CNR1 (0.64) CNR1ALDH1A1ATRHTTKMO
SCHEMBL11192637 0.84 NPC1 (0.65) ALDH1A1HPGDHSD17B10ATRKMT2A
SCHEMBL10663620 0.84 CYP17A1 (0.76) CNR1ALDH1A1HSD17B10CYP11B1CYP11B2
SCHEMBL29611891 0.84 NPC1 (0.65) ALDH1A1HPGDHSD17B10ATRKMT2A
SCHEMBL19538968 0.84 CYP3A4 (0.60) CNR1ALDH1A1HSD17B10KMT2ALMNA
SCHEMBL19531638 0.84 HTT (0.67) CNR1ALDH1A1HPGDKMT2ALMNA
SCHEMBL19706697 0.82 ALDH1A1 (0.53) CNR1ALDH1A1HPGDHSD17B10CYP11B1
SCHEMBL1570408 0.82 HPGD (0.53) CNR1ALDH1A1HPGDHSD17B10CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204360-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2020-08-26 EP disclosed
US-20170312292-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 US disclosed
WO-2016055028-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-04-14 WO disclosed
WO-2007130743-A2 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. (US) 2007-11-15 WO disclosed
EP-0056260-A1 Pyridinyl-substituted-benz imidazole derivatives and preparation STERLING DRUG INC. (US) 1982-07-21 EP disclosed
EP-0055453-A2 5-(Pyridinyl)-benzimidazole derivatives and preparation STERLING DRUG INC. (US) 1982-07-07 EP disclosed
US-4335132-A 5-(Py-Y)-1H-benzimidazol-2-ols and 5-(Py-Y-)-1H-benzimidazole-2-thiols STERLING DRUG, INC. (US) 1982-06-15 US disclosed
US-4331671-A 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use STERLING DRUG INC. (US) 1982-05-25 US disclosed
US-4127583-A Preparation of 3-(pyridinyl)-2-cyclohexene-1-ones STERLING DRUG INC. (US) 1978-11-28 US disclosed
US-4118557-A Cyclic alkylidenyl N-(lower-alkyl)-3-(pyridinyl)anilinomethylenemalonates STERLING DRUG INC. (US) 1978-10-03 US disclosed
US-4111946-A Preparation of 3-(pyridinyl)-2-cyclohexen-1-ones STERLING DRUG INC. (US) 1978-09-05 US disclosed
US-4075217-A Conversion of 3-(pyridinyl)-2-cyclohexen-1-one to 3-(pyridinyl)anilines STERLING DRUG INC. (US) 1978-02-21 US disclosed
US-4026900-A 3-(Pyridinyl)-2-cyclohexen-1-ones STERLING DRUG INC. (US) 1977-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170312292-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, CREBBP, HDAC1 CNR1 867/4885ALDH1A1 1533/4885HPGD 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.